The Global NASH Congress programme creates a collaborative environment in which you can create enduring relationships across the full range of disciplines engaged in NASH research & drug discovery and development.

• Learn how to integrate NAFLD Screening into secondary and tertiary care
• Discover the regulatory pathways for approval of biomarkers in NAFLD patients
• Review the current and potential biomarkers for staging
• Investigate if targeting fructose metabolism offers a NAFLD/NASH therapy
• Hear how belapectin, a galectin-3 (Gal-3) inhibitor, is in development for the prevention of oesophagal varices in patients with NASH cirrhosis
• Explore the Epidemiology of NAFLD

To know more about The 4th Global NASH Congress please click here.